Reset filter
Keywords
Coronary Disease ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

139 Search results.

Relevance Rating New first Old first

Persönliches Interview SHIP-Trend-1 Herz-Kreislauf-Erkrankungen

- 2/13/21 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Herz-Kreislauf-Erkrankungen
Herz-Kreislauf-Erkrankungen form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name TREND.TREND1.INT.KHK.KHK. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Endpoint Hospitalisation for heart failure GSK study Chronic Coronary Heart Disease NCT00799903

- 9/20/21 - 1 form, 3 itemgroups, 43 items, 1 language
Itemgroups: Investigator section,CEC Section,CEC Status
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Endpoint Hospitalisation for heart failure - Repeating form (Scheduled visits)

Lifestyle Questionnaire GSK study Chronic Coronary Heart Disease NCT00799903

- 9/20/21 - 1 form, 11 itemgroups, 73 items, 1 language
Itemgroups: Diet,Alcoholic drinks,Weekly activity,Physical activity,Health-related limitations in physical activity,Symptoms limiting physical activity,Sleep,Stress assessment,Lifestyle comparison before and after heart problem,Lifestyle since first heart problem,Socio-economic
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Lifestyle Questionnaire.

Eligibility Coronary Artery Disease NCT00287690

- 9/20/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00287690

EUROASPIRE III- Coronary heart disease HRI Interview Questionnaire - HRI Interview Questionnaire

- 9/17/21 - 1 form, 12 itemgroups, 272 items, 1 language
Itemgroups: Demographic Information,Smoking,Diet/Body weight,Physical activity,Blood pressure,Cholesterol and Diabetes,Risk factor awareness and targets,Lifestyle changes,Risk perception,Medication,Family history of cardiovascular disease,Physical measurements,Blood sample
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

EUROASPIRE III- Coronary heart disease HRI Record Questionnaire - HRI Record Questionnaire

- 9/17/21 - 1 form, 3 itemgroups, 133 items, 1 language
Itemgroups: Inclusion criteria,Personal information,HRI Record Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

Eligibility Coronary Artery Disease NCT00233792

- 10/6/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent; ODM derived from: https://clinicaltrials.gov/show/NCT00233792

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Coronary heart disease (Koronare Herzerkrankung)

- 10/1/20 - 1 form, 6 itemgroups, 26 items, 1 language
Itemgroups: Patient-ID,Diagnostic analysis: cardiac symptoms,Diagnostic analysis: severity,Ischemia diagnostic procedure,Course of treatment: Intervention,Medication during transport to hospital
A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. In this questionnaire specific items on coronary heart disease patients are collected.

Liver imaging GSK study Chronic Coronary Heart Disease NCT00799903

- 6/17/20 - 1 form, 11 itemgroups, 60 items, 1 language
Itemgroups: Date of hepatic or liver imaging test,method used for imaging test,images technically adequate,liver size,liver texture,diffuse and/or geographic fatty infiltrate of the liver,Ascites present,Focal Hepatic Lesions characterisable,Gallstones or gallbladder lesions,Biliary ductal lesions,Portal/Hepatic vein abnormalities
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Liver imaging - Repeating form (Unscheduled/Dynamic visit)

Gene Expression Test for Coronary Artery Disease Diagnosis NCT01594411 - Eligibility Criteria

- 7/7/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Primary Care Providers Use of a Gene Expression Test in Coronary Artery Disease Diagnosis; ODM derived from: https://clinicaltrials.gov/show/NCT01594411 This is a prospective, multi-center study examining the clinical impact of the Corus CAD (Age/Sex/Gene Expression score - ASGES) assay in approximately 250 evaluable subjects with no history of obstructive coronary artery disease who now present with chest pain or anginal-equivalent symptoms to a primary care physician (PCP) for evaluation.

Eligibility Coronary Heart Disease NCT02509013

- 3/12/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02509013

Eligibility Coronary Heart Disease NCT02435797

- 3/12/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction; ODM derived from: https://clinicaltrials.gov/show/NCT02435797

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial